Drug Profile
Research programme: protozoal infection therapeutics - Pfizer/Drugs for Neglected Diseases Initiative
Alternative Names: DNDi-2035804; DNDI-5421; DNDI-5610; OXALEISHLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Developer Drugs for Neglected Diseases Initiative Foundation; Pfizer
- Class Antiprotozoals; Organic boron compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Leishmaniasis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in African-trypanosomiasis in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Chagas-disease in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Leishmaniasis in USA